NASDAQ:MRKR Marker Therapeutics Q4 2025 Earnings Report $1.05 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.08 +0.03 (+2.95%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Marker Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.21Beat/MissBeat by +$0.17One Year Ago EPSN/AMarker Therapeutics Revenue ResultsActual Revenue$1.10 millionExpected Revenue$0.68 millionBeat/MissBeat by +$421.44 thousandYoY Revenue GrowthN/AMarker Therapeutics Announcement DetailsQuarterQ4 2025Date3/18/2026TimeBefore Market OpensConference Call DateWednesday, March 18, 2026Conference Call Time7:00AM ETUpcoming EarningsMarker Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Marker Therapeutics Earnings HeadlinesMarker Highlights Expanded Manufacturing Support For MT-601September 22, 2026 | rttnews.comMarker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced TherapiesSeptember 22, 2026 | globenewswire.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.October 4 at 1:00 AM | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)August 22, 2026 | theglobeandmail.comMarker Therapeutics Sets Date for 2026 Annual MeetingMay 19, 2026 | theglobeandmail.comMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comSee More Marker Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email. Email Address About Marker TherapeuticsMarker Therapeutics (NASDAQ:MRKR) (NASDAQ: MRKR) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s approach uses multiTAA-specific T cells, which are designed to recognize and attack multiple tumor-associated antigens rather than a single target. Marker Therapeutics is developing these therapies for patients with solid tumors and certain hematologic malignancies. The company’s lead investigational product, MT-601, is an autologous multiTAA-specific T-cell therapy being evaluated in clinical development, including for pancreatic cancer. Marker Therapeutics has also pursued additional multiTAA-specific T-cell programs for other cancers. Its therapies are investigational and have not been established as safe or effective for commercial use. Marker Therapeutics is headquartered in Houston, Texas. The company was previously known as TapImmune and adopted the Marker Therapeutics name as it shifted its focus toward its multiTAA-specific T-cell platform. Its programs are developed through clinical research and collaborations intended to support the advancement of personalized cancer immunotherapies.View Marker Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
